AzTrials
AzTrials

Elective Thoracic SurgeryNCT02032342

Selective Lobar Blockade and Bronchial Blockers

A study testing Endobronchial double lumen tube, Arndt® blocker and Cohen blocker in people with Elective Thoracic Surgery and One Lung Ventilation, run by Imam Abdulrahman Bin Faisal University at 1 site in Saudi Arabia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Selective lobar blockade (SLB) is a specific technique that allows collapse of the operated lobe during thoracic surgery while the other lobes are ventilated. It is associated with the improvement of arterial oxygenation during one lung ventilation (OLV) for thoracic with providing adequate surgical access. Read more about this study

Who is it for?
Ages 18 to 70 years
What is being tested?
Endobronchial double lumen tube, Arndt® blocker and Cohen blocker
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
60 participants
Where
1 siteSaudi Arabia
Study dates
Jan 2014to Sep 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • American Society of Anesthesiologists physical class of II to III
  • Elective thoracic surgery
  • no previous thoracic surgery on the operation
  • the lung lobe containing or adjacent to the lesion can be targeted for collapse

Who cannot join

  • emergency procedures
  • pneumonectomy
  • bilobectomy
  • history of infectious lesions
  • history of bleeding lung lesions
  • tracheotomy
  • Body mass index > 35 kg/m2
  • difficult airways

Trial locations and contacts

1 site in 1 country.

Saudi Arabia1 site
  • Dammam University

    Khobar, Eastern Province, 31952

Other trials in Saudi Arabia

About this study

Official title: Selective Lobar Blockade: A Randomized Trial of Three Bronchial Blockers

Selective lobar blockade (SLB) is a specific technique that allows collapse of the operated lobe during thoracic surgery while the other lobes are ventilated. It is associated with the improvement of arterial oxygenation during one lung ventilation (OLV) for thoracic with providing adequate surgical access. The purpose of this study is to compare the efficacy of three bronchial blockers, namely an Arndt® wire-guided endobronchial blocker, a Cohen Flexi-tip endobronchial blocker or a Fuji Uni-blocker, for achieving selective lobar collapse.

Read the detailed description

Prevention of hypoxemia associated with one-lung ventilation (OLV) during video-assisted thoracoscopic surgery (VATS) or open thoracotomy has a priority for anesthetists.

Selective lobar blockade (SLB) is a specific technique that allows collapse of the operated lobe during thoracic surgery while the other lobes are ventilated. SLB has been recommended to enhance the safety of OLV in patients with previous pulmonary resection requiring subsequent resection or in patients with limited pulmonary reserve resulting from severe pulmonary disease.1

One of the advantages of SLB is the improvement of arterial oxygenation in patients undergoing lobectomy with providing adequate lobar collapse for surgical access.2 Similarly, selective left lower lobar blockade during lower esophageal surgery provides a lower intraoperative intrapulmonary shunt and a better perioperative arterial oxygenation.3

SLB can be achieved with a Coopdech endobronchial blocker tube (COOPDECH™, Osaka, Japan),3an Arndt® wire-guided endobronchial blocker (Cook Inc., Bloomington, IN)4-6 or with an embolectomy catheter,7 can be used through a single-lumen endotracheal tube (ETT), attached to a single-lumen ETT with a sided channel (Univent tube),2 or placed under direct laryngoscopy.7

Up to best of the authors' knowledge, there is no consensus on the best technique for selective lobar blockade for thoracic surgery.

The purpose of this study is to compare the efficacy of three bronchial blockers, namely an Arndt® wire-guided endobronchial blocker, a Cohen Flexi-tip endobronchial blocker (Cook Critical Care, Bloomington, IN) or a Fuji Uni-blocker (Fuji Systems, Tokyo, Japan), for achieving selective lobar collapse. It is generally accepted that bronchial blockers perform better clinically when positioned in the longer left mainstem bronchus versus the shorter right bronchus.9 However, this could not be extended for the SLB. Thus, the present study will include both sides thoracic procedures and studied patients will be stratified to the side on which their surgery will be performed, right or left.

An independent investigator who will be blind to the study groups and who will not be involved in the patients' management will collect the saved recorded patient data by the attending anesthesiologists.

The surgeons, who will be absent from the operating room during DLT or bronchial blocker placement, will be blind to randomization and to the isolation device by means of an opaque sheet placed over the lung isolation device.

In all patients, standard monitoring, including radial arterial catheterization, and state and response entropy (SE and RE, respectively) will be applied. Patients will received either a thoracic epidural or a paravertebral catheter before the induction of anesthesia for open thoracotomy or patient-controlled systemic morphine after VATS, for postoperative analgesia.

Anesthetic technique will be standardized in all studied patients. The same senior anesthesiologists (> 5 years' experience), who are experienced in thoracic surgery, OLV, and the use of a FOB for DLT and bronchial blockers placement, will give the anesthetic, will place all of the isolation devices in the studied groups and will not be involved in the patient's assessment.

General anesthesia will be induced with propofol (2-3 mg/kg) and fentanyl (2-3 µg/kg). Cisatracurium (0.2 mg/kg) will be given to facilitate the placement of the isolation device. Anesthesia will be maintained with 0.7-1.5 minimum alveolar concentration (MAC) of sevoflurane or total intravenous anesthesia according to each center's protocol to maintain the SE values < 50 and the difference between RE and SE < 10. fentanyl 0.5µg/kg increments will be administered when the SE values > 50, the difference between RE and SE >10, and the heart rate and MAP are >20% of the baseline values despite a target sevoflurane MAC ≥ 1.5. Cisatracurium increments will be used to maintain surgical relaxation as indicated by train-of-4 monitoring.

Patients' two lungs will be ventilated, with a fraction of inspired oxygen (FiO2) of 0.5 in air, tidal volume (VT) of 8 mL/kg predicted body weight (PBW), inspiratory to expiratory [I: E] ratio of 1:2.5 and positive end expiratory pressure (PEEP) of 5 cm H2O, and respiratory rate adjusted to achieve an arterial carbon dioxide tension of 35-45 mm Hg. Peak airway pressure will be limited to 35 cm H2O and a fresh gas flow (FGF) < 2 L/min will be used.

The patients' tracheas will be intubated using a Macintosh laryngoscope with either an appropriately sized left-sided DLT (DLT group)10 or a minimum 7.5-mm internal diameter (ID) ETT for women and 8.0-mm ID ETT for men, which will be connected to a dedicated multiport airway adapter to allow continuous ventilation of the patients during the placement of the bronchial blockers (bronchial blockers groups).

In the DLT group; the correct placement of the DLT will be assessed by using an FOB. Then, the lumen of the nondependent lung will be clamped and left open to air to facilitate unilateral lung collapse.

In the bronchial blockers groups; all bronchial blockers will be placed via the ETT according to the manufacturers' recommended instructions. To achieve selective lobe collapse during surgery, the bronchial blocker will be advanced and directed to block selectively the desired operated lobe (or lobes) only; under vision with a pediatric FOB. The bronchial blocker will be placed deeply into the desired bronchus to minimize the chance of dislodgment back into the mainstem bronchus or trachea. If surgery will be performed in either the right middle or lower lobe, both lobes will be collapsed while the right upper lobe will be ventilated. If surgery will be performed in either the left lower or upper lobe, the left upper or lower lobe will be collapsed, respectively, while the remaining lobe will be ventilated. For the Arndt® blocker, once the blocker will be in an optimal position, the wire loop will be removed to use the wire channel for suction. To facilitate the selected lobar collapse, a barrel part of a 1-mL insulin syringe will be attached to the suction port of the bronchial blocker, and will be connected to suction.

OLV will be initiated using a VT of 6 mL/kg PBW, FiO2 of 0.3-1.0 to maintain SaO2 > 92%, whereas the I: E ratio, PEEP, respiratory rate, and FGF will be maintained as during two-lung ventilation. Recruitment maneuvers for the dependent lung will be repeated at 30-minute intervals by raising the inspiratory pressure up to 40 cmH2O for 10 seconds.

The patients will be then turned to the lateral decubitus position for surgery, the position of the DLT or the bronchial blocker will be checked with FOB. All operations were performed by the same surgeons.

If the lung collapse is not satisfactory or if any ventilation problem occurs during surgery, such as an increase of peak pressure, the FOB will be passed to reposition the bronchial cuff of the DLT or the bronchial blocker; if it is not appropriately positioned in the desired bronchus.

Patient will be withdrawn from the study and total operative lung collapse will be considered if the surgeon rates the VAS of the operative field conditions as 30 mm or less despite the confirmation of the appropriate position of the isolation device with FOB.

Intraoperative hypoxemia will be defined as decreases in SaO2 less than 90% will be treated with increasing of FiO2 to 1.0. Addition of low level of 2 cm H2O of CPAP to the ventilated lung (or lobes) will be considered if the former fails to correct hypoxemia.

At the end of surgery, the operative lung will be re-expanded, two-lung ventilation will be resumed, sevoflurane will be discontinued and the residual neuromuscular block will be antagonized.

Before extubation, FOB will be performed in all patients to observe whether there was any damage to the tracheal or bronchial mucosa. For the Arndt® blocker group, the bronchial blocker will be deflated and then withdrawn together with the multiport connector to prevent shredding the plastic balloon over the blocker port.

Each of the four lung isolation groups will be further subdivided into two subgroups according to the side of surgery to right-sided and left-sided subgroups.

Sample Size Calculation:

A power analysis of data from our pilot study on a similar surgical population indicated that we need to study 14 subjects in each group to detect a 15-mm true difference in the mean visual analog scale (VAS) rating of the to rate the deflation of the target lung lobe with a standard deviation (S.D.) of 1.22, a type-I error of 0.0083 (0.05 / 6 possible comparisons) and a power of 90%. We will add 10% more patients for a final sample size of 60 patients to account for patients dropping out during the study.

Being tested
Endobronchial double lumen tube, Arndt® blocker, Cohen blocker, Fuji Uni-blocker

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Endobronchial double lumen tubeDevice

    Endobronchial double lumen tube for one lug ventilation

  • Arndt® blockerDevice

    Arndt® blocker for selective lobar deflation

  • Cohen blockerDevice

    Cohen blocker for selective lobar deflation

  • Fuji Uni-blockerDevice

    Fuji Uni-blocker foe selective lobar deflation

Study groups in NCT02032342
Study groupRoleWhat they receive
Fuji Uni-blockerActive comparatorFuji Uni-blocker for selective lobar deflation
Receives: Device: Fuji Uni-blocker
Cohen blockerActive comparatorCohen blocker for selective lobar deflation
Receives: Device: Cohen blocker
Arndt® blockerActive comparatorArndt® blocker for selective lobar deflation
Receives: Device: Arndt® blocker
Endobronchial double lumen tubePlacebo comparatorEndobronchial double lumen tube for one lung ventilation
Receives: Device: Endobronchial double lumen tube

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. operative field conditions

    The surgeons will be asked to rate the deflation of the target lung lobe using a 100-mm visual analog scale (VAS) (0: full inflated; 100: completely deflated).

    Measured: participants will be followed for the duration of surgery, an expected average of 3 hours

Secondary outcomes (7)
  1. time required to initially position the assigned device

    the time between the passing of the double lumen tube or tracheal tube past the vocal cords and the confirmation by fiberoptic bronchoscope of the satisfactory position of the device

    Measured: up to 8 minutes after position the assigned device

  2. number of intraoperative FOB examinations

    The number of intraoperative FOB examinations to assure proper position during surgery

    Measured: for 2 hours after start of surgery

  3. number of lung isolation device malpositionings

    The number of lung isolation device malpositionings after initial placement

    Measured: for 2 hours after start of surgery

  4. Arterial oxygenation

    Arterial oxygenation

    Measured: 5 min after induction, 15 min after start of one lung ventilation, 30 min after start of one lung ventilation, 60 min after start of one lung ventilation

  5. Heart rate

    Heart rate

    Measured: 5 min after induction, 15 min after start of one lung ventilation, 30 min after start of one lung ventilation, 60 min after start of one lung ventilation

  6. Blood pressure

    Blood pressure

    Measured: 5 min after induction, 15 min after start of one lung ventilation, 30 min after start of one lung ventilation, 60 min after start of one lung ventilation

  7. Cost

    Cost of the used devices

    Measured: for 1 hour after surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Jan 2014 (estimated)
  2. Study startJan 2014
  3. Primary completionAug 2016
  4. Study completionSep 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
60 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02032342
Sponsor's protocol ID
Anesth-Nov13(1)
Status last verified
May 2018
First submitted
7 Jan 2014
Last updated
24 May 2018
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A study testing Endobronchial double lumen tube, Arndt® blocker and Cohen blocker in people with Elective Thoracic Surgery and One Lung Ventilation, run by Imam Abdulrahman Bin Faisal University at 1 site in Saudi Arabia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 24 May 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Saudi Arabia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

operative field conditions (time frame: participants will be followed for the duration of surgery, an expected average of 3 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 May 2018.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in